396 related articles for article (PubMed ID: 29651584)
21. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
22. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
23. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
24. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
Cerveira N; Bizarro S; Teixeira MR; Mariz JM
Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
[TBL] [Abstract][Full Text] [Related]
25. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Atallah E; Schiffer CA; Weinfurt KP; Zhang MJ; Radich JP; Oehler VG; Pinilla-Ibarz J; Deininger MWN; Lin L; Larson RA; Mauro MJ; Moore JO; Ritchie EK; Shah NP; Silver RT; Wadleigh M; Cortes J; Thompson J; Guhl J; Horowitz MM; Flynn KE
BMC Cancer; 2018 Apr; 18(1):359. PubMed ID: 29609532
[TBL] [Abstract][Full Text] [Related]
26. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
27. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
28. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Fava C; Rege-Cambrin G; Dogliotti I; Cerrano M; Berchialla P; Dragani M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Elena C; Pregno P; Gozzini A; Capodanno I; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; Stagno F; Cavazzini F; Sgherza N; Giai V; Luciano L; Russo S; Musto P; Caocci G; Sorà F; Iuliano F; Lunghi F; Specchia G; Pane F; Ferrero D; Baccarani M; Saglio G
Haematologica; 2019 Aug; 104(8):1589-1596. PubMed ID: 30819917
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
30. Treatment-free remission in chronic myeloid leukemia.
Molica M; Naqvi K; Cortes JE; Paul S; Kadia TM; Breccia M; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Dec; 17(12):686-696. PubMed ID: 31851157
[TBL] [Abstract][Full Text] [Related]
31. Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
Astrugue C; Bénard A; Bosco-Levy P; Dulucq S; Rouyer M; Lassalle R; Hayes N; Mahon FX
Value Health; 2021 May; 24(5):683-690. PubMed ID: 33933237
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
33. Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Söderlund S; Persson I; Ilander M; Guilhot J; Hjorth-Hansen H; Koskenvesa P; Richter J; Saussele S; Mustjoki S; Olsson-Strömberg U
Leuk Res; 2020 Mar; 90():106310. PubMed ID: 32058176
[TBL] [Abstract][Full Text] [Related]
34. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Hochhaus A; Ernst T
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):106-112. PubMed ID: 34889388
[TBL] [Abstract][Full Text] [Related]
35. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Pavlovsky C; Abello Polo V; Pagnano K; Varela AI; Agudelo C; Bianchini M; Boquimpani C; Centrone R; Conchon M; Delgado N; Funke V; Giere I; Luise I; Meillon L; Moiraghi B; Navarro JR; Pilleux L; Prado AI; Undurraga S; Cortes J
Blood Adv; 2021 Dec; 5(23):4855-4863. PubMed ID: 34438444
[TBL] [Abstract][Full Text] [Related]
36. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
[TBL] [Abstract][Full Text] [Related]
37. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
38. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract][Full Text] [Related]
39. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.
Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Çiftçiler R; Akın MG; Erat Z; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
